Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalolitovolrelimab maintenance after SBRT in non-small cell lung cancer
ChiCTR2500112263Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apalolitovolrelimab in non-small cell lung cancer (NSCLC), sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Objective response rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
apalolitovolrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500112263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112263.